Programme 2 : PISTER (Parametrization of Immune Suppression, Tumor Escape and Resistance)

Developing tools of functional personalised medicine by combining predictive algorithms and cell tests in oncology.

Coordinators: Philippe Juin, Catherine Pellat and Stephane Minvielle

The PISTER programme brings together teams of clinicians, academics and researchers from the CHUN, the ICO, the CHUA, the CRCINA, the LS2N, the LAREMA and The Jean Leray Mathematics Laboratory.

It is underpinned by the multidisciplinary expertise of the players in the Loire region in clinical and translational research in oncology (molecular mechanisms of apoptosis, resistance and tumour heterogeneity, oncoimmunology, virus oncolytics, …) associated with a network of mathematicians and bioinformaticians.

The PISTER programme is dedicated to tumour resistance mechanisms and its parameters. Its objective is to provide a multiparametric and functional definition of the evolution of resistance, based on a combination of molecular models, systemic markers and specific phenotypes. It is also about defining and validating more efficient and targeted therapeutic approaches.

The PISTER programme is organised into 4 axes which correspond to the first 3 steps of the patients’ care pathway and also an axis for integration of the complex data generated :

Le programme PISTER est organisé en 4 axes correspondant aux 3 premières étapes du parcours de soins des malades en plus d’un axe d’intégration des données complexes générées :

Axis 6: Study of the molecular and functional heterogeneity of tumours and their microenvironment on diagnosis.

Head Scientists : Martine Amiot & Yves Delneste

The main problem consists of decoding the molecular and immune-related characteristics of tumours at the moment of diagnosis, whilst deducing the presence and the characterisation of de novo resistant subclones using short-term trials.

Axis 7: Evaluation of residual tumour clones and/or systemic response to cytotoxic treatment and their modification under treatment.

Head Scientists : Julie Gavard & Cyrille Touzeau

The main problem consists of decoding the molecular and immune-related characteristics of tumours at the moment of diagnosis, whilst deducing the presence and the characterisation of de novo resistant subclones using short-term trials.

Axis 8: Definition of molecular and functional heterogeneity of tumours and their microenvironment at relapse.

Head Scientists : Catherine Pellat & Catherine Guette

This is about studying the chemo/immune resistance of cancer cells at relapse and determining if and how new approaches directly targeting mitochondrial integrity (selective BH3 mimetic agents), the sensitivity to viral infections (OV) and the myeloid cells (ICI selective), could constitute therapeutic alternatives.

Axis 9: Mathematical integration of the complex data collected.

Head Scientists : Bertrand Michel & Stéphane Minvielle

The objective is to mathematically integrate the complex data collected into the programme.

Start typing and press Enter to search